231 related articles for article (PubMed ID: 37478670)
1. High-dose chemotherapy sensitizes locally advanced esophageal squamous cell carcinoma to PD-1 blockade for a higher pathological complete response rate and survival.
Wang P; Lei M; Weng G; Huang R; Lin H; Wei W; Chen Y; He H; Chen P; Zhang D; Chen W; Zhou H; Gao P; Liu S; Wang F
Transl Oncol; 2023 Oct; 36():101736. PubMed ID: 37478670
[TBL] [Abstract][Full Text] [Related]
2. Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial).
Ding C; Guo Y; Zhou Y; He Y; Chen C; Zhang M; Guo X
BMC Cancer; 2023 Dec; 23(1):1237. PubMed ID: 38102553
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
Liu J; Yang Y; Liu Z; Fu X; Cai X; Li H; Zhu L; Shen Y; Zhang H; Sun Y; Chen H; Yu B; Zhang R; Shao J; Zhang M; Li Z
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338088
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma.
Shen D; Chen Q; Wu J; Li J; Tao K; Jiang Y
J Gastrointest Oncol; 2021 Feb; 12(1):1-10. PubMed ID: 33708420
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE).
Chen Y; Ren M; Li B; Meng Y; Wang C; Jiang P; Song T; Yang J; Zhu D; Yu Q
J Thorac Dis; 2023 Dec; 15(12):6761-6775. PubMed ID: 38249875
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1).
Zhang Z; Hong ZN; Xie S; Lin W; Lin Y; Zhu J; Yang X; Lin Z; Lin J; Kang M
Ann Transl Med; 2021 Nov; 9(21):1623. PubMed ID: 34926667
[TBL] [Abstract][Full Text] [Related]
8. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
9. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
Front Immunol; 2022; 13():853922. PubMed ID: 35720312
[TBL] [Abstract][Full Text] [Related]
10. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
[TBL] [Abstract][Full Text] [Related]
11. The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study.
Yin GQ; Li ZL; Li D
Cancer Manag Res; 2022; 14():2133-2141. PubMed ID: 35795828
[TBL] [Abstract][Full Text] [Related]
12. Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma.
Wang H; Jiang Z; Wang Q; Wu T; Guo F; Xu Z; Yang W; Yang S; Feng S; Wang X; Chen S; Cheng C; Chen W
Eur J Cancer; 2023 Jun; 186():196-210. PubMed ID: 37045666
[TBL] [Abstract][Full Text] [Related]
13. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).
Yan X; Duan H; Ni Y; Zhou Y; Wang X; Qi H; Gong L; Liu H; Tian F; Lu Q; Sun J; Yang E; Zhong D; Wang T; Huang L; Wang J; Chaoyang Wang ; Wang Y; Wan Z; Lei J; Zhao J; Jiang T
Int J Surg; 2022 Jul; 103():106680. PubMed ID: 35595021
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study.
Xia P; Li P; Wu S; Wang Y; Ye P; Zhang C; Hu J; Kidane B; Lampridis S; Velotta JB; Wakefield CJ; Zhu L; Wang L
Ann Transl Med; 2022 Sep; 10(18):991. PubMed ID: 36267734
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma.
Lv H; Tian Y; Li J; Huang C; Sun B; Gai C; Li Z; Tian Z
Front Oncol; 2022; 12():864533. PubMed ID: 35574384
[TBL] [Abstract][Full Text] [Related]
16. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
Li Y; Zhou A; Liu S; He M; Chen K; Tian Z; Li Y; Qin J; Wang Z; Chen H; Tian H; Yu Y; Qu W; Xue L; He S; Wang S; Bie F; Bai G; Zhou B; Yang Z; Huang H; Fang Y; Li B; Dai X; Gao S; He J
BMC Med; 2023 Mar; 21(1):86. PubMed ID: 36882775
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma.
Chen F; Qiu L; Mu Y; Sun S; Yuan Y; Shang P; Ji B; Wang Q
Front Surg; 2022; 9():893372. PubMed ID: 35983558
[TBL] [Abstract][Full Text] [Related]
18. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
19. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.
Xing W; Zhao L; Zheng Y; Liu B; Liu X; Li T; Zhang Y; Ma B; Yang Y; Shang Y; Fu X; Liang G; Yuan D; Qu J; Chai X; Zhang H; Wang Z; Lin H; Liu L; Ren X; Zhang J; Gao Q
Front Immunol; 2021; 12():772450. PubMed ID: 34938292
[TBL] [Abstract][Full Text] [Related]
20. Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
Liu J; Zhu L; Huang X; Lu Z; Wang Y; Yang Y; Ye J; Gu C; Lv W; Zhang C; Hu J
J Cancer Res Clin Oncol; 2024 Mar; 150(3):161. PubMed ID: 38536527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]